Percutaneous coronary intervention (PCI) using a drug-eluting stent (DES) leads to less re-stenosis than PCI using a bare metal stent (BMS), however there is still controversy whether use of a DES for severe coronary disease leads to an acceptable outcome in patients with diabetes mellitus (DM). In this study 8159 lesions were treated in 6739 patients (mean age 68.9 years) with coronary artery disease. Use of a DES significantly decreased the re-stenosis rate compared with BMS in both DM (9.6% versus 21.3%) and non-DM (9.5% versus 17.1%) patients.
Introduction
Introduced about a decade after coronary artery bypass grafting, percutaneous coronary intervention (PCI) has come to be preferred, because it is less invasive, and it is now widely used to treat coronary artery disease. 1,2 Technological improvements, especially the development of coronary stents, have made it possible to treat complex lesions. 3 -5 However, in previous randomized trials coronary artery bypass grafting was superior to PCI for patients with diabetes or multivessel coronary artery disease when using plain balloon angioplasty or a bare metal stent (BMS). 6, 7 The differences in outcome between coronary artery bypass grafting and PCI were mainly associated with re-stenosis of the treated lesions and target lesion revascularization (TLR).
The recent advent of drug-eluting stents (DES) has dramatically reduced the rate of re-stenosis after PCI, and DES are particularly superior to BMS in PCI for small vessels, whether or not the coronary disease is associated with diabetes mellitus (DM). Several trials, however, have demonstrated that DES did not reduce subsequent rates of major adverse clinical events or mortality, although they did reduce the rate of target lesion revascularization compared with the use of a BMS. 8, 9 The objective of the present study was to evaluate the clinical outcomes of PCI with a stent in the presence and absence of DM in Japanese patients with coronary artery disease.
Patients and methods

PATIENTS, SUCCESS CRITERIA AND TREATMENTS
Consecutive patients who underwent PCI for coronary artery disease at Kanazawa University Hospital and affiliate hospitals (see Appendix for a list of affiliate hospitals) between January 2006 and December 2008 were eligible for enrolment into the study. The indications for PCI included stable angina pectoris, unstable angina and acute myocardial infarction. Patients who underwent PCI but were treated without stenting, using only balloon dilatation, thrombectomy or directional coronary atherectomy, were excluded.
All procedural decisions, including device selection and adjunctive pharmacotherapy, were made at the discretion of the individual PCI operator. Intravascular ultrasonography was used at the operator's discretion. Procedural (angiographic) success was defined as residual stenosis of < 25%. The definition of clinical success included angiographic success and the in-hospital absence of acute myocardial infarction, congestive heart failure and cardiac death. Procedural and clinical success were evaluated at the time the patient was discharged.
All patients who underwent PCI with a stent received dual antiplatelet therapy comprising aspirin (100 mg/day) and clopidogrel (75 mg/day) or ticlopidine (200 mg/day), and continued this therapy for an appropriate period.
This study was certified by the Ethics Committee of Kanazawa University.
CLINICAL FOLLOW-UP
All patients were evaluated clinically during a follow-up visit to the outpatient clinic and were recommended to receive follow-up coronary angiography at least 6 months after the PCI procedure. Angiographic results and clinical symptoms were used to evaluate the clinical outcome. Binary re-stenosis was defined as ≥ 50% stenosis at the target lesion.
The occurrence of major adverse cardiac events (MACE), defined as sudden cardiac death, acute coronary syndrome-related K Uchiyama, H Ino, K Hayashi et al. Stent treatment of coronary artery disease in diabetes target lesions and TLR, was recorded. Coronary risk factors, comprising DM (fasting blood glucose > 126 mg/dl or glycated haemoglobin > 6.5%), hypertension (blood pressure > 130/85 mmHg), hypercholesterol aemia (total cholesterol > 220 mg/dl) and smoking, were also checked and evaluated for association with re-stenosis.
STATISTICAL ANALYSES
Continuous variables were expressed as mean ± SD and were compared using Student's t-test and analysis of variance. Categorical data were compared using the χ 2 test or Fisher's exact test. MACE-free survival distributions were calculated by Kaplan-Meier analysis and differences were assessed using the log-rank test. A P-value < 0.05 was considered statistically significant. All data analyses were performed using StatView ® J 5.0 software (SAS Institute, Cary, NC, USA).
Results
A total of 7660 consecutive patients (5745 men) with 9392 lesions underwent PCI for coronary artery disease at Kanazawa University Hospital and affiliate hospitals between January 2006 and December 2008 and were eligible for enrolment into this study. Angiography was carried out in 5570 (72.7%) of these patients. Of the 9392 total number of lesions, 1233 were treated without stenting (959 using only balloon dilatation and 274 with thrombectomy or directional coronary atherectomy) so were excluded from the analysis. The remaining 8159 lesions in 6739 patients (mean ± SD age 68.9 ± 10.5 years; 5103 men) were evaluated and stenting was successful in 8129 (99.6%) lesions from 6709 (99.6%) patients. Because this was a multicentre study, with data obtained from many hospitals (see Appendix), it was not possible to obtain data on all variables for all patients. Table 1 and were similar in the BMS and DES groups with the exceptions of the number of lesions in patients with acute coronary syndrome (ACS) and the numbers of patients with DM as a coronary risk factor. A total of 2421 lesions were associated with ACS: 1702 (48.1%) and 719 (15.6%) BMS-and DEStreated lesions, respectively (P < 0.0001). DM was associated with 3070 patients: 1171 (39.9%) BMS-treated patients and 1899 (49.9%) DES-treated patients (P < 0.0001).
IN-HOSPITAL OUTCOMES
Angiographic success was obtained in 6618 (98.2%) and clinical success in 6476 (96.1%) patients. Within 30 days after the procedure, stent-related MACE were observed in 74 (1.1%) patients, including 49 (0.7%) deaths and 25 (0.4%) cases of ACS, comprising 21 (0.3%) cases of myocardial infarction and four (0.05%) cases of unstable angina associated with angiographically confirmed subacute stent thrombosis (Table 2 ). The frequency of MACE up to 30 days after the procedure was significantly higher in the BMS group than in the DES group (P < 0.0001).
LONG-TERM OUTCOMES
Re-stenosis and TLR
All cases of successful stenting (8129 lesions from 6709 patients) were clinically followed up for a period of 3 years and 5975 lesions (73.5%) underwent follow-up coronary angiography after the initial procedure (mean ± SD follow-up interval 7.3 ± 4.9 months). The number of lesions for which restenosis was carried out was significantly lower in the DES group than in the BMS group: 445 of 4623 (9.6%) lesions versus 661 of 3536 (18.7%) lesions (relative risk 1.94 for the BMS group versus the DES group; P < 0.01; Fig. 1) . Similarly, the rate of TLR was also significantly lower in the DES group than in the BMS group: 327 of 4623 (7.1%) lesions versus 472 of 3536 (13.6%) lesions (relative risk 1.46 for the BMS group versus the DES group; P < 0.01; Fig. 1 ). The longterm cumulative frequency of MACE in patients with ACS was similar in the BMS and DES groups: 83/1702 (4.9%) and 26/719 (3.6%) patients, respectively. (Fig. 2) . There was no significant effect of other coronary risk factors with regard to the occurrence of re-stenosis.
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Event-free survival analysis
Evaluation of event-free survival after stenting was examined in the BMS and DES groups by Kaplan-Meier analysis (Fig. 3) . In one-and two-vessel disease, event-free survival decreased until about 200 and 300 days after stenting in patients treated with BMS and DES, respectively, and was significantly higher in the DES group than in the BMS group (P < 0.001). In three-vessel disease, event-free survival was also higher in the DES group than in the BMS group (P < 0.001) and the pattern of the Kaplan-Meier survival curves was similar to that of one-and two-vessel disease. In terms of patients fitted with a DES, event-free survival did not differ significantly between patients with one-or two-vessel disease and those with three-vessel disease, however, among patients treated with a BMS the long-term outcome of three-vessel disease was significantly worse than that of one-or twovessel disease (P < 0.001). Event-free survival also decreased until 200 and 300 days after stenting of patients with LMCA disease in the BMS and DES groups, respectively, but the eventual survival rate did not differ significantly between these two groups. 
Discussion
The present study revealed that PCI in a realworld population was safe and feasible, with an angiographic procedural success rate of 98.2%, and the BMS and DES treatments were associated with low rates of MACE. Although the in-hospital MACE rate in the BMS group was significantly (P < 0.0001) higher than that in the DES group, this was considered to be because of the significantly higher incidence of patients with ACS who were treated with a BMS. There was no significant difference in MACE between the two groups when comparison was restricted only to patients showing ACS after stenting.
Implantation of a DES could reduce the risk of TLR by 40%, although it might also carry a minor risk of stent thrombosis and myocardial infarction within 2.7 years compared with BMS implantation. 10, 11 In the present study, the relative risk of TLR following BMS implantation was 1.46 that of DES, however there were no differences between DES and BMS in the long-term risks of MACE (death, myocardial infarction or unstable angina associated with stent thrombosis). This may be explained by the fact that intravascular ultrasound and continuous dual antiplatelet therapy were frequently used.
It has been shown that DM is one of the most substantial risk factors for re-stenosis after stent implantation, with odds ratios of 1.9 -2.5. 12 In the present study, using a DES led to a decrease in the rate of TLR compared with using a BMS, particularly in patients with DM. This result was consistent with a previous study in which TLR rates associated with a DES, during 4 years of follow-up, were 9.7% and 8.7% for patients with and without DM, respectively, and rates associated with a BMS were 22.4% and 16.4%, respectively. 13 Re-stenotic intimal hyperplasia in patients with DM may differ from that in patients without DM in terms of cellular aspects. 14, 15 For example, diabetic vascular smooth muscle cells have been shown to exhibit increased rates of proliferation, leading to luminal narrowing. 14 A polymer coating, that releases anti-inflammatory and antiproliferative agents, is used in DES 15 and this may effectively prevent intimal proliferation in patients with or without DM. 16 We have reported previously that the use of a DES could suppress out-stent plaque progression, which was closely related to the progression of intimal hyperplasia 17 and this effect may be particularly relevant in the presence of DM.
The late outcome of one-and two-vessel disease, three-vessel disease and LMCA disease after DES and BMS implantation was evaluated in the present study. Event-free survival did not differ significantly between patients with one-or two-vessel disease and those with three-vessel coronary disease treated with a DES however, among patients treated with a BMS, the long-term outcome of three-vessel disease was worse than that of one-or two-vessel disease, probably because multivessel disease is often associated with multiple coronary risk factors. 18 The outcome of LMCA lesions treated with a BMS or DES was worse than that of non-LMCA lesions. Although the eventual survival rate was not significantly different between the BMS and DES groups in LMCA disease, survival in patients fitted with a DES was superior to those with BMS in patients with non-LMCA lesions. Differences were particularly notable in bifurcation lesions. It is commonly thought that stenting for bifurcation lesions is associated with a high re-stenosis rate and this might have a 19 We consider, therefore, that LMCA lesions should not be treated by DES implantation alone but additionally with interventions such as coronary artery bypass grafting, or by combining PCI with bypass surgery.
The present study had several limitations. First, because it was not randomized, the results might have been influenced by potential biases, however a relatively large number of patients (> 5000) were examined which may have minimized the effect of this limitation. Secondly, access to all information about the patients' medications, except for the antiplatelet agents used, was not available. This may have had some influence on the results, particularly regarding the long-term outcome. Indeed, several studies have reported different conclusions, suggesting superiority of the DES over the BMS in LMCA lesions. 20 -23 Further large prospective trials, in which the effects of several coronary risk factors and lesion characteristics, especially LMCA lesions, are considered, may demonstrate differences between DES and BMS in severe coronary lesions, including those of the LMCA. This evaluation of the clinical outcomes treated with stents in a real-world population of patients with coronary artery disease in Japan showed that the use of a DES dramatically decreased the rate of re-stenosis compared with the use of a BMS, particularly in patients with DM. However, very late re-stenosis was observed in a few cases treated with a DES, probably because of delayed healing of the stenting lesion. There was no statistically significant difference in event-free survival after stenting of patients with LMCA disease between the BMS and DES groups. We suggest careful treatment after using DES for severe coronary disease, including LMCA lesions, in patients with DM.
